Alterity Therapeutics (ATHE) Income from Continuing Operations (2009 - 2024)
Alterity Therapeutics' (ATHE) quarterly Income from Continuing Operations came in at 12755923.06 in Q2 2024, down 36.64% year-on-year from 20132903.52 in Q3 2023, and down 36.64% quarter-over-quarter from 9335327.2 in Q2 2023.
Alterity Therapeutics (ATHE) Income from Continuing Operations (2009 - 2024) Analysis & Trends
Alterity Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 12755923.06 for Q2 2024.
- On a quarterly basis, Income from Continuing Operations fell 36.64% year-over-year to 12755923.06 in Q2 2024; TTM through Jun 2024 was 35270321.65, a 12.56% decrease from a year earlier, with the FY2025 full-year figure at 7823457.08, up 38.81% from the prior year.
- Income from Continuing Operations declined to 12755923.06 in Q2 2024 per ATHE's latest filing, from 9335327.2 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9325709.73 in Q2 2022 and bottomed at 12755923.06 in Q2 2024.
- The 3-year median for Income from Continuing Operations is 9335327.2 (2023), against an average of 10472320.0.
- Across the five-year window, Income from Continuing Operations fell 0.1% in 2023 and tumbled 36.64% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 9325709.73 in 2022, then slipped by 0.1% to 9335327.2 in 2023, then tumbled by 36.64% to 12755923.06 in 2024.
- Per Business Quant, the three latest ATHE Income from Continuing Operations figures stand at 12755923.06 (Q2 2024), 9335327.2 (Q2 2023), and 9325709.73 (Q2 2022).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alterity Therapeutics | 29.68 Bn | 29.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -12.76 Mn |
| Jun 30, 2023 | -9.34 Mn |
| Jun 30, 2022 | -9.33 Mn |
| Dec 31, 2019 | -3.85 Mn |
| Jun 30, 2019 | -8.82 Mn |
| Dec 31, 2018 | -3.83 Mn |
| Jun 30, 2018 | -6.38 Mn |
| Dec 31, 2017 | -2.78 Mn |
| Jun 30, 2017 | -5.38 Mn |
| Dec 31, 2016 | -2.74 Mn |
| Jun 30, 2010 | -4.34 Mn |
| Jun 30, 2009 | -5.71 Mn |